Icotrokinra Hydrochloride Patent Expiration

Icotrokinra Hydrochloride was first introduced by Janssen Biotech Inc in its drug Icotyde on Mar 17, 2026.


Icotrokinra Hydrochloride Patents

Given below is the list of patents protecting Icotrokinra Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Icotyde US11939361 Compositions Of Peptide Inhibitors Of Interleukin-23 Receptor Nov 19, 2041 Janssen Biotech
Icotyde US11845808 Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases Jan 14, 2041 Janssen Biotech
Icotyde US12552836 Jul 12, 2039 Janssen Biotech



Icotrokinra Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Icotrokinra Hydrochloride Generic API Manufacturers

Given below is the list of companies who have filed for Icotrokinra Hydrochloride generic, along with the locations of their manufacturing plants worldwide.